NCT07209163 - Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

Tazemetostat

Tazemetostat 800mg, twice once daily (BID), orally

DRUG

Linperlisib

"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Linperlisib: 60 mg once daily (QD) and 60 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Linperlisib RP2D in patients with peripheral T-cell lymphoma with co-RHOA/TET2mut."

DRUG

Golidocitinib

"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Lgolidocitinib: 150 mg every other day (QOD) and 150 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Golidocitinib RP2D in patients with peripheral T-cell lymphoma without co-RHOA/TET2mut."

All Listed Sponsors

lead

Ruijin Hospital

OTHER